



US008389542B2

(12) **United States Patent**  
**Ueno et al.**

(10) **Patent No.:** **US 8,389,542 B2**  
(45) **Date of Patent:** **\*Mar. 5, 2013**

(54) **DOSAGE UNIT COMPRISING A  
PROSTAGLANDIN ANALOG FOR TREATING  
CONSTIPATION**

(75) Inventors: **Ryuji Ueno**, Potomac, MD (US); **Myra  
L. Patchen**, Fairfax, VA (US)

(73) Assignee: **Sucampo AG**, Zug (CH)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **13/330,942**

(22) Filed: **Dec. 20, 2011**

(65) **Prior Publication Data**

US 2012/0088824 A1 Apr. 12, 2012

**Related U.S. Application Data**

(62) Division of application No. 10/293,516, filed on Nov.  
14, 2002, now Pat. No. 8,097,653.

(60) Provisional application No. 60/331,316, filed on Nov.  
14, 2001.

(51) **Int. Cl.**

**A61K 31/44** (2006.01)

**A61K 31/34** (2006.01)

**A61K 31/19** (2006.01)

(52) **U.S. Cl.** ..... **514/302; 514/469; 514/573**

(58) **Field of Classification Search** ..... **514/302,**  
**514/469**

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,158,062 A 6/1979 Caton et al.

5,117,042 A 5/1992 Ueno et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**

EP 0 310 305 A2 4/1989

EP 0 424 156 A2 4/1991

(Continued)

**OTHER PUBLICATIONS**

A. Robert, J.E. Nezamis, C. Lancaster, A.J. Hanchar, and M.S. Klep-  
per, Enteropooling Assay: A Test for Diarrhea Produced by  
Prostaglandins; Prostaglandins, May 1976, vol. 11, No. 5, 809-828.

(Continued)

*Primary Examiner* — Melenie McCormick


*Assistant Examiner* — Gigi Huang

(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC

(57) **ABSTRACT**

A dosage unit for treating constipation in a human patient is  
described. The dosage unit of the invention includes a halo-  
genated prostaglandin analog and a pharmaceutically suitable  
excipient. The dosage unit relieves constipation without sub-  
stantial side effects. In particular, the dosage unit includes a  
prostaglandin (PG) analog represented by Formula (I) and/or  
its tautomers, and a pharmaceutically suitable excipient,  
wherein the dosage unit contains the PG analog in an amount  
of 24 µg+/-10%:

Formula (I)



**13 Claims, 3 Drawing Sheets**

